v3.25.2
Related party transactions
12 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Alps Life Science Inc [Member]    
IfrsStatementLineItems [Line Items]    
Related party transactions

 

13. Related party transactions

 

(a)Identify related parties

 

For the purposes of the consolidated financial statements, parties are considered to be related to the Group if the Group has the ability, directly or indirectly, to control the party or exercise significant influence over the party in making financial and operating decisions, or vice versa, or where the Group and the party are subject to common control. Related parties may be individuals or other entities.

 

Related parties also include key management personnel. Key management personnel are defined as those persons having authority and responsibility for planning, directing and controlling the activities of the Group either directly or indirectly. The key management personnel of the Group include directors of the Group.

 

 

13. Related party transactions (Cont’d)

 

(b)Significant related party transactions and balances

 

Amount due from associates represent non-trade balances which are unsecured, interest free and receivable on demand.

 

Amount due to associates represent non-trade balances which are unsecured, interest free and repayable on demand.

 

Amount due to directors represent non-trade advances, interest free and repayable on demand.

 

Related party transactions have been entered in the normal course of business under negotiated terms. In addition to the related party balances disclosed elsewhere in the consolidated financial statements, the related party transactions of the Group are as follows:

 

   2025   2024 
   USD   USD 
         
Associates:          
Alps Globemedics          
Agent commission   196,531    120,189 
Management fee income   13,534    12,916 
           
Related party:          
Director          
Agent commission   45,590    18,102 
Consultancy fee   -    51,663 
Patent License Agreement*   -    707,028 

 

*During the financial year ended 31 March 2024, the Company entered into a Patent License Agreement with a director of the Company, wherein the director shall grant to the Company an exclusive, royalty-free and non-transferable right and license all the patents stated in the agreement.

 

(c)Compensation of key management personnel

 

The remuneration of key management personnel during the financial year are as follows:

 Schedule of key management personnel

   2025   2024 
   USD   USD 
         
Fee   79,988    71,811 
Salaries and other emoluments   185,871    162,726 
Defined contribution plans   20,555    19,255 
           
Total   286,414    253,792 

 

 
Cilo Cybin Holdings Limited [member]    
IfrsStatementLineItems [Line Items]    
Related party transactions

 

18. RELATED PARTIES

The following related party relationships existed or were identified throughout the year:

 

Key Management Personnel    
Gabriel Theron   Chief Executive Officer and shareholder
Jessica Moodley - Theron   Non-Executive Director
Reshoketswe Maggy Ledwaba   Chief Financial Officer

 

There are outstanding related party balances at the end of the financial year. Refer to note 4 for details relating to the loans from Gabriel Theron.

 

Cilo Cybin Pharmaceutical (Pty) Ltd

 

Cilo Cybin entered into a sub lease agreement with Cilo Cybin Pharmaceutical (Pty) Ltd in the current financial year. The lease payments are R52,908 per month, escalating at 8% per annum and the lease liability was calculated using the company’s incremental borrowing rate at 11.75%.

 

The sublease was entered into on an arm’s length basis and is consistent with market terms. All amounts were settled in the ordinary course of business. Further details relating to the lease are above in the lease liability note 7.

14. RELATED PARTIES

Related party transactions

 

The following related party relationships existed or were identified throughout the year:

 

Key Management Personnel

 

  Gabriel Theron Chief Executive Director and shareholder
  Jessica Moodley - Theron Non-Executive Director

 

Refer to note 4 for details relating to the loans from G. Theron.